Alterations in cGMP, soluble guanylate cyclase, phosphodiesterase 5, and B-type natriuretic peptide induced by chronic increased pulmonary blood flow in lambs

Pediatric Pulmonology

Volumn 42, Issue 11, 2007, Pages 1057-1071

  Oishi, Peter ^a   Sharma, Shruti ^c   Grobe, Albert ^d   Azakie, Anthony ^a   Harmon, Cynthia ^a   Johengen, Michael J ^a   Hsu, Jong Hau ^a   Fratz, Sohrab ^e   Black, Stephen M ^c   Fineman, Jeffrey R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d UNIVERSITY OF MONTANA   (United States)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

B type natriutertic peptide; cGMP; Congenital heart disease; Increased pulmonary blood flow; Phosphodiesterase 5; Soluble guanylate cyclase

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; GUANYLATE CYCLASE; PHOSPHODIESTERASE V; PROTEIN SUBUNIT;

AORTA GRAFT; AORTOPULMONARY VASCULAR GRAFT; ARTICLE; BLOOD VESSEL GRAFT; COMPARATIVE STUDY; EXPERIMENTAL STUDY; GESTATION PERIOD; IMMUNOHISTOCHEMISTRY; LAMB; LUNG BLOOD FLOW; NEWBORN; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; TISSUE DISTRIBUTION; WESTERN BLOTTING;

ANIMALS; ANIMALS, NEWBORN; ANIMALS, SUCKLING; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GUANYLATE CYCLASE; HEART DEFECTS, CONGENITAL; NATRIURETIC PEPTIDE, BRAIN; PULMONARY CIRCULATION; SHEEP;

EID: 36248984865     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.20696     Document Type: Article

References (53)

1. Celermajer DS, Cullen S, Deanfield JE. Impairment of endothelium- dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation 1993;87:440-446.
2. Steinhorn RH, Fineman JR. The pathophysiology of pulmonary hypertension in congenital heart disease. Artif Organs 1999;23: 970-974.
3. Ignarro LJ, Harbison RG, Wood KS, Kadowitz PJ. Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid. J Pharmacol Exp Ther 1986;237:893-900.
4. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest 1986;78:1-5.
5. Kamisaki Y, Saheki S, Nakane M, Palmieri JA, Kuno T, Chang BY, Waldman SA, Murad F. Soluble guanylate cyclase from rat lung exists as a heterodimer. J Biol Chem 1986;261:7236-7241.
6. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995;75:725-748.
7. Torphy TJ, Zhou HL, Burman M, Huang LB. Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis. Mol Pharmacol 1991;39:376-384.
8. Thomas MK, Francis SH, Corbin JD. Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J Biol Chem 1990;265:14964-14970.
9. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-328.
10. Russell IA, Zwass MS, Fineman JR, Balea M, Rouine-Rapp K, Brook M, Hanley FL, Silverman NH, Cahalan MK. The effects of inhaled nitric oxide on postoperative pulmonary hypertension in infants and children undergoing surgical repair of congenital heart disease. Anesth Analg 1998;87:46-51.
11. Atz AM, Wessel DL. Inhaled nitric oxide in the neonate with cardiac disease. Semin Perinatol 1997;21:441-455.
12. Miller OI, Tang SF, Keech A, Pigott NB, Beller E, Celermajer DS. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. Lancet 2000;356:1464-1469.
13. Watanabe H, Ohashi K, Takeuchi K, Yamashita K, Yokoyama T, Tran QK, Satoh H, Terada H, Ohashi H, Hayashi H. Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 2002;71:398-402.
14. Stocker C, Penny DJ, Brizard CP, Cochrane AD, Soto R, Shekerdemian LS. Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. Intensive Care Med 2003;29:1996-2003.
15. Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 2005;111:3274-3280.
16. Reddy VM, Meyrick B, Wong J, Khoor A, Liddicoat JR, Hanley FL, Fineman JR. In utero placement of aortopulmonary shunts. A model of postnatal pulmonary hypertension with increased pulmonary blood flow in lambs. Circulation 1995;92:606-613.
17. Reddy VM, Wong J, Liddicoat JR, Johengen M, Chang R, Fineman JR. Altered endothelium-dependent responses in lambs with pulmonary hypertension and increased pulmonary blood flow. Am J Physiol 1996;271:H562-H570.
18. Black SM, Fineman JR, Steinhorn RH, Bristow J, Soifer SJ. Increased endothelial NOS in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol 1998;275: H1643-H1651.
19. Black SM, Sanchez LS, Mata-Greenwood E, Bekker JM, Steinhorn RH, Fineman JR. sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001;281:L1051-L1057.
20. Kouchoukos NT, Blackstone EH, Kirklin JW. Surgical implications of pulmonary hypertension in congenital heart disease. Adv Cardiol 1978;22:225-231.
21. Gutierrez JA, Parry AJ, McMullan DM, Chapin CJ, Fineman JR. Decreased surfactant proteins in lambs with pulmonary hypertension secondary to increased blood flow. Am J Physiol Lung Cell Mol Physiol 2001;281:L1264-L1270.
22. Black SM, Johengen MJ, Ma ZD, Bristow J, Soifer SJ. Ventilation and oxygenation induce endothelial nitric oxide synthase gene expression in the lungs of fetal lambs. J Clin Invest 1997;100: 1448-1458.
23. Rabinovitch M, Keane JF, Norwood WI, Castaneda AR, Reid L. Vascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defects. Circulation 1984;69:655-667.
24. Rabinovitch M, Reid LM. Quantitative structural analysis of the pulmonary vascular bed in congenital heart defects. Cardiovasc Clin North Amer 1977;11:149-169.
25. Burrows FA, Rabinovitch M. The pulmonary circulation in children with congenital heart disease: morphologic and morphometric considerations. Can Anaesth Soc J 1985;32:364-373.
26. Steinhorn RH, Russell JA, Lakshminrusimha S, Gugino SF, Black SM, Fineman JR. Altered endothelium-dependent relaxations in lambs with high pulmonary blood flow and pulmonary hypertension. Am J Physiol Heart Circ Physiol 2001;280:H311-H317.
27. Yandle TG. Biochemistry of natriuretic peptides. J Intern Med 1994;235:561-576.
28. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988;332:78-81.
29. McGrath MF, de Bold ML, de Bold AJ. The endocrine function of the heart. Trends Endocrinol Metab 2005;16:469-477.
30. Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 2003;45:249-254.
31. Cowley CG, Bradley JD, Shaddy RE. B-type natriuretic peptide levels in congenital heart disease. Pediatr Cardiol 2004;25:336-340.
32. Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart 2003;89:875-878.
33. Wong J, Reddy VM, Hendricks-Munoz K, Liddicoat JR, Gerrets R, Fineman JR. Endothelin-1 vasoactive responses in lambs with pulmonary hypertension and increased pulmonary blood flow. Am J Physiol 1995;269:H1965-H1972.
34. Heidersbach RS, Johengen MJ, Bekker JM, Fineman JR. Inhaled nitric oxide, oxygen, and alkalosis: dose-response interactions in a lamb model of pulmonary hypertension. Pediatr Pulmonol 1999;28:3-11.
35. Castro LR, Verde I, Cooper DM, Fischmeister R. Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation 2006;113:2221-2228.
36. Su J, Scholz PM, Weiss HR. Differential effects of cGMP produced by soluble and particulate guanylyl cyclase on mouse ventricular myocytes. Exp Biol Med (Maywood) 2005;230:242-250.
37. Rho EH, Perkins WJ, Lorenz RR, Warner DO, Jones KA. Differential effects of soluble and particulate guanylyl cyclase on Ca(2+) sensitivity in airway smooth muscle. J Appl Physiol 2002; 92:257-263.
38. Zolle O, Lawrie AM, Simpson AW. Activation of the particulate and not the soluble guanylate cyclase leads to the inhibition of Ca2+ extrusion through localized elevation of cGMP. J Biol Chem 2000;275:25892-25899.
39. Buechler WA, Nakane M, Murad F. Expression of soluble guanylate cyclase activity requires both enzyme subunits. Biochem Biophys Res Commun 1991;174:351-357.
40. Pyriochou A, Papapetropoulos A. Soluble guanylyl cyclase: more secrets revealed. Cell Signal 2005;17:407-413.
41. Sharina IG, Martin E, Thomas A, Uray KL, Murad F. CCAAT-binding factor regulates expression of the beta1 subunit of soluble guanylyl cyclase gene in the BE2 human neuroblastoma cell line. Proc Natl Acad Sci USA 2003;100 11523-11528.
42. Jurado S, Sanchez-Prieto J, Torres M. Differential expression of NO-sensitive guanylyl cyclase subunits during the development of rat cerebellar granule cells: regulation via N-methyl-D-aspartate receptors. J Cell Sci 2003;116:3165-3175.
43. Moreno L, Gonzalez-Luis G, Cogolludo A, Lodi F, Lopez-Farre A, Tamargo J, Villamor E, Perez-Vizcaino F. Soluble guanylyl cyclase during postnatal porcine pulmonary maturation. Am J Physiol Lung Cell Mol Physiol 2005;288:L125-L130.
44. Bland RD, Ling CY, Albertine KH, Carlton DP, MacRitchie AJ, Day RW, Dahl MJ. Pulmonary vascular dysfunction in preterm lambs with chronic lung disease. Am J Physiol Lung Cell Mol Physiol 2003;285:L76-L85.
45. Li D, Laubach VE, Johns RA. Upregulation of lung soluble guanylate cyclase during chronic hypoxia is prevented by deletion of eNOS. Am J Physiol Lung Cell Mol Physiol 2001;281:L369-L376.
46. Andreopoulos S, Papapetropoulos A. Molecular aspects of soluble guanylyl cyclase regulation. Gen Pharmacol 2000;34: 147-157.
47. Black SM, Johengen MJ, Soifer SJ. Coordinated regulation of genes of the nitric oxide and endothelin pathways during the development of pulmonary hypertension in fetal lambs. Pediatr Res 1998;44:821-830.
48. Tzao C, Nickerson PA, Russell JA, Gugino SF, Steinhorn RH. Pulmonary hypertension alters soluble guanylate cyclase activity and expression in pulmonary arteries isolated from fetal lambs. Pediatr Pulmonol 2001;31:97-105.
49. Black SM, Bekker JM, McMullan DM, Parry AJ, Ovadia B, Reinhartz O, Lakshminrushimha S, Mata-Greenwood E, Steinhorn RH, Fineman JR. Alterations in nitric oxide production in 8-week-old lambs with increased pulmonary blood flow. Pediatr Res 2002;52:233-244.
50. Filippov G, Bloch DB, Bloch KD. Nitric oxide decreases stability of mRNAs encoding soluble guanylate cyclase subunits in rat pulmonary artery smooth muscle cells. J Clin Invest 1997;100: 942-948.
51. Hanson KA, Ziegler JW, Rybalkin SD, Miller JW, Abman SH, Clarke WR. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am J Physiol 1998;275:L931-L941.
52. Murray F, MacLean MR, Pyne NJ. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol 2002;137:1187-1194.
53. Maclean MR, Johnston ED, McCulloch KM, Pooley L, Houslay MD, Sweeney G. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther 1997;283:619-624.